Acorn Capital Advisors LLC Makes New Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Acorn Capital Advisors LLC purchased a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,442,308 shares of the company's stock, valued at approximately $6,260,000. Cardiff Oncology makes up approximately 3.4% of Acorn Capital Advisors LLC's holdings, making the stock its 12th largest position. Acorn Capital Advisors LLC owned approximately 2.82% of Cardiff Oncology as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. acquired a new position in Cardiff Oncology in the 4th quarter valued at approximately $5,609,000. Geode Capital Management LLC grew its position in shares of Cardiff Oncology by 5.9% in the fourth quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock valued at $4,266,000 after purchasing an additional 54,646 shares during the last quarter. State Street Corp increased its position in Cardiff Oncology by 3.4% in the 3rd quarter. State Street Corp now owns 832,652 shares of the company's stock worth $2,223,000 after buying an additional 27,628 shares during the period. Northern Trust Corp raised its stake in Cardiff Oncology by 8.9% during the 4th quarter. Northern Trust Corp now owns 337,092 shares of the company's stock valued at $1,463,000 after purchasing an additional 27,489 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock worth $1,253,000 after acquiring an additional 117,514 shares during the period. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, February 28th.

Cardiff Oncology Stock Down 5.0 %

CRDF traded down $0.14 during trading on Monday, hitting $2.68. The company's stock had a trading volume of 937,778 shares, compared to its average volume of 1,121,853. The firm's 50 day moving average price is $3.29 and its two-hundred day moving average price is $3.48. The stock has a market capitalization of $178.29 million, a price-to-earnings ratio of -2.85 and a beta of 1.81. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $5.64.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.